Pruritus care shifts toward more tailored treatment plans: full analysis

Managing pruritus in companion animals remains one of small animal practice’s most common, and most frustrating, clinical challenges, and current recommendations are increasingly focused on structured, multimodal care rather than reflexively reaching for a single antipruritic. In Veterinary Practice News, Therese Castillo frames the issue around a practical reality many clinicians know well: treating the root cause is ideal, but often incomplete, delayed, or not fully feasible, so therapy has to reduce suffering, protect skin barrier function, and preserve the human-animal bond while diagnostics continue. (veterinarypracticenews.com)

That approach aligns closely with the 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines, which lay out separate but overlapping pathways for flea allergy, food allergy, canine atopic dermatitis, and feline atopic skin syndrome. The guidance emphasizes confirming or ruling out ectoparasites, infections, and diet-responsive disease, then matching therapy to flare severity and chronicity. In dogs, mild to moderate pruritus may be managed with options such as oclacitinib or lokivetmab, while more severe inflammation may still call for glucocorticoids in selected patients. Topical therapy, flea control, and management of secondary bacterial or yeast disease remain foundational, not optional add-ons. (meridian.allenpress.com)

The treatment toolbox is now broad, but each option comes with tradeoffs. Merck Veterinary Manual notes that oclacitinib has a fast onset, often within 24 hours, and is used for both acute flares and long-term management, while lokivetmab can begin working within 1 to 3 days and is dosed by injection every 2 to 8 weeks. Glucocorticoids still offer reliable short-term suppression of itch and inflammation, but long-term use raises well-known concerns including polyuria, polydipsia, polyphagia, skin atrophy, infection risk, and iatrogenic hyperadrenocorticism. Reviews of canine atopic dermatitis likewise support topical therapy and allergen-specific strategies as steroid-sparing tools, especially in recurrent disease. (merckvetmanual.com)

One important development since many earlier itch-management frameworks were published is the arrival of Zenrelia (ilunocitinib). FDA approved the once-daily oral JAK inhibitor on September 19, 2024, for dogs at least 12 months old to control pruritus associated with allergic dermatitis and to control atopic dermatitis. But the launch has not been frictionless. FDA later highlighted safety concerns tied to immunosuppression and vaccination response, including a recommendation to avoid use around vaccination windows, and in January 2025 the agency issued a warning letter to Elanco over promotional materials it said overstated safety or effectiveness. That makes Zenrelia clinically relevant, but also a reminder that newer options may arrive with meaningful label and communication nuances that practices need to understand before widespread adoption. (fda.gov)

Expert consensus in the literature continues to support individualized drug selection over brand-first thinking. A peer-reviewed clinical guideline on antipruritic drugs in dogs concludes that systemic glucocorticoids, oclacitinib, lokivetmab, ciclosporin, and antihistamines each have roles depending on whether the goal is acute flare control, chronic management, or adjunctive care, with stronger evidence for some agents than others. AAHA similarly notes that oclacitinib is more effective in some patients, while lokivetmab works better in others. For cats, the picture is narrower: feline pruritus often requires heavier reliance on diagnostics, environmental and parasite control, diet trials, and careful use of anti-inflammatory medications because labeled targeted options remain limited compared with dogs. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary teams, this is less a story about a single product than about how itch medicine is maturing. Pruritus is a symptom with many causes, and fast relief still matters, especially when self-trauma, sleep disruption, secondary infection, or pet parent distress are driving the visit. But the stronger clinical message is that durable success depends on sequencing: rule out parasites, identify infection, assess diet and environmental triggers, choose the safest agent for the individual patient, and revisit the plan when response is incomplete. That’s especially important in patients with concurrent disease, those receiving NSAIDs, those with infection risk, or cases where long-term steroid exposure could create more problems than it solves. (veterinarypracticenews.com)

For clinics, the operational implications are real. Teams need clear protocols for flare visits versus chronic management, communication tools that help pet parents understand why “itch relief” and “diagnosis” are not the same thing, and awareness of evolving safety guidance for newer immunomodulatory drugs. The expanding canine market may improve flexibility, but it also increases the need for medication reviews, vaccine timing discussions, and informed consent around adverse-event monitoring. In other words, the standard of care is becoming more personalized, and more dependent on follow-up than on the initial prescription alone. (fda.gov)

What to watch: The next phase will likely be shaped by real-world experience with Zenrelia, continued use of established agents such as Apoquel and Cytopoint, and whether future guideline updates further refine drug selection by phenotype, flare pattern, comorbidity profile, and species-specific evidence gaps. (fda.gov)